BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 28515254)

  • 21. The role of JAK2 inhibitors in MPNs 7 years after approval.
    Passamonti F; Maffioli M
    Blood; 2018 May; 131(22):2426-2435. PubMed ID: 29650801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes R; Mesa RA
    Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy for myeloproliferative neoplasms: when, which agent, and how?
    Geyer HL; Mesa RA
    Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
    How J; Story C; Connors JM
    Postgrad Med; 2021 Jun; 133(5):508-516. PubMed ID: 33480813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
    Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
    Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.
    Kim SY; Bae SH; Bang SM; Eom KS; Hong J; Jang S; Jung CW; Kim HJ; Kim HY; Kim MK; Kim SJ; Mun YC; Nam SH; Park J; Won JH; Choi CW
    Korean J Intern Med; 2021 Jan; 36(1):45-62. PubMed ID: 33147902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
    Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
    Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
    [No Abstract]   [Full Text] [Related]  

  • 29. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future therapies for the myeloproliferative neoplasms.
    Scherber R; Mesa RA
    Curr Hematol Malig Rep; 2011 Mar; 6(1):22-7. PubMed ID: 21080242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
    Bose P; Verstovsek S
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1393-1403. PubMed ID: 27756180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
    Sankar K; Stein BL
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1539-1545. PubMed ID: 30545998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
    Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
    Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
    Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
    Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging treatments for classical myeloproliferative neoplasms.
    Vannucchi AM; Harrison CN
    Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs).
    Pemmaraju N; Mesa R
    Hematology Am Soc Hematol Educ Program; 2015; 2015():649-51. PubMed ID: 26637784
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms.
    Kiladjian JJ
    Am Soc Clin Oncol Educ Book; 2015; ():e389-96. PubMed ID: 25993201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
    O'Sullivan JM; Harrison CN
    Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.